Last reviewed 2026-05-25 · How we verify

JAB-30355

Jacobio Pharmaceuticals Co., Ltd. · Phase 1 active Small molecule ✓ Verified May 2026

JAB-30355 is a Small molecule drug developed by Jacobio Pharmaceuticals Co., Ltd.. It is currently in Phase 1 development.

JAB-30355 is a small molecule being studied in a Phase 1/2a clinical trial for patients with advanced solid tumors harboring the TP53 Y220C mutation. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JAB-30355.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	JAB-30355
Sponsor	Jacobio Pharmaceuticals Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

JAB-30355 CI brief — competitive landscape report
JAB-30355 updates RSS · CI watch RSS
Jacobio Pharmaceuticals Co., Ltd. portfolio CI

Frequently asked questions about JAB-30355

What is JAB-30355?

JAB-30355 is a Small molecule drug developed by Jacobio Pharmaceuticals Co., Ltd..

Who makes JAB-30355?

JAB-30355 is developed by Jacobio Pharmaceuticals Co., Ltd. (see full Jacobio Pharmaceuticals Co., Ltd. pipeline at /company/jacobio-pharmaceuticals-co-ltd).

What development phase is JAB-30355 in?

JAB-30355 is in Phase 1.

Manufacturer: Jacobio Pharmaceuticals Co., Ltd. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing